4.6 Article

Flat Irregular Retinal Pigment Epithelium Detachments in Chronic Central Serous Chorioretinopathy and Choroidal Neovascularization

期刊

AMERICAN JOURNAL OF OPHTHALMOLOGY
卷 159, 期 5, 页码 890-903

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2015.02.002

关键词

-

资金

  1. Alcon, USA
  2. Bausch and Lomb, USA
  3. Novartis, Switzerland
  4. Allergan, USA
  5. Pfizer, USA
  6. Takeda, Japan
  7. Bayer, Germany
  8. Alimera, USA
  9. Zeiss, Germany
  10. Sony, Japan
  11. Alcon, Switzerland
  12. Zeiss-Humphrey, Germany
  13. Heidelberg, Germany

向作者/读者索取更多资源

PURPOSE: To evaluate the incidence of flat, irregular pigment epithelium detachments (PEDs) in chronic central serous chorioretinopathy (CSC) and to determine whether they are consistent with active choroidal neovascularization (CNV). DESIGN: Retrospective case series. METHODS: Review of medical records of patients with chronic CSC who were examined in the Ophthalmology Department of Lariboisiere Hospital between June 1, 2007 and May 31, 2013. Multimodal imaging of the fundus, including optical coherence tomography (OCT), fundus autofluorescence, and indocyanine green and fluorescein angiography, was available in most cases. RESULTS: One hundred and ten patients with chronic CSC were identified. Fifty-three eyes of 38 patients showed flat irregular PED on macular OCT examination. Mean age was 58.6 +/- 13.2 years. Twenty-eight patients (73.6%) patients were male. Fifteen patients (39.4%) had bilateral flat irregular PEDs. The mean follow-up duration was 14.6 years (range: 2-39 years). PEDs were suggestive of type 1 CNV in 10 eyes, but no other signs of AWED, specifically no drusen, were present. In the remaining 43 eyes, flat irregular PEDs were stable over time (mean follow-up duration: 15 years) with no evidence of active neovascularization. CONCLUSION: Although the possible occurrence of type 1 CNV complicating the course of chronic CSC should not be ignored, all cases of flat irregular PED should not be mistaken for active CNV and systematically treated with anti-VEGF. Nevertheless, in some cases with worsened vision not responding to usual CSC therapy, anti-VEGF could be considered as a therapeutic test to rule out the presence of secondary CNV. (C) 2015 by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据